929,626 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 929,626 shares of the biopharmaceutical company’s stock, valued at approximately $31,040,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Ultragenyx Pharmaceutical by 14.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 29,984 shares in the last quarter. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $454,000. American Century Companies Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $366,000. M&T Bank Corp boosted its holdings in Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 1,192 shares during the period. Finally, Amundi boosted its holdings in Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after buying an additional 93,189 shares during the period. Institutional investors own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the topic of a number of analyst reports. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $45.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $59.22.

Ultragenyx Pharmaceutical Trading Down 0.7%

Shares of NASDAQ:RARE opened at $26.26 on Friday. The company has a 50 day moving average of $28.59 and a 200 day moving average of $25.03. The stock has a market cap of $2.59 billion, a P/E ratio of -4.50 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the prior year, the firm posted ($1.17) EPS. Ultragenyx Pharmaceutical’s revenue was up 28.5% on a year-over-year basis. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -3.99 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares in the company, valued at approximately $528,429.75. The trade was a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 8,552 shares of company stock worth $207,455 in the last three months. Corporate insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.